A continuation study of TAK-279 for adults with ulcerative colitis and Crohn's disease
Summary description of the study
Crohn's disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), a serious, long-term condition of the intestines that can cause pain and swelling (inflammation) in the gut. CD is a severe condition that can affect any part of the digestive tract from the mouth to the anus and typically causes inflammation of the intestines. UC causes inflammation of the inner lining of certain parts of the intestines, such as the colon and the rectum. Zasocitinib, also known as TAK-279, is an orally administered medication that inhibits inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 and TAK-279-UC-2001. This means that participants who responded to treatment with Zasocitinib in either of the two parent studies can continue to benefit from treatment in this study. The main objective is to determine how safe Zasocitinib is and to assess whether it reduces intestinal inflammation and symptoms with prolonged use.
(BASEC)
Intervention under investigation
This is an open-label continuation study, meaning that participants are aware that they will be receiving Zasocitinib. Adults who have responded to treatment and completed week 52 in either of the two main studies can participate in this continuation study. Participants will receive Zasocitinib daily for up to 2 years (from week 0 to week 108). The maximum study duration for an individual participant is just over 2 years (112 weeks), which includes a 4-week safety follow-up period.
(BASEC)
Disease under investigation
Crohn's disease (CD) and ulcerative colitis (UC)
(BASEC)
Adults aged 18 to 75 years who suffer from IBD and have responded to treatment in the main study (TAK-279-CD-2001 or TAK-279-UC-2001) can participate in this study. (BASEC)
Exclusion criteria
Potential study participants who have been diagnosed with abnormal cell growth at any time during the main study or at the beginning of this continuation study during an endoscopy cannot participate. (BASEC)
Trial sites
Basel, Bern
(BASEC)
Sponsor
Sponsor: Takeda Development Center Americas Inc. Namita Singh 500 Kendall Street, Cambridge, Massachusetts, 02142, USA Email: namita.singh@takeda.com phone: 13105626094 Sponsor’s representative in Switzerland : Jens Lachmann ICON Clinical Research (Switzerland) GmbH c/o Experfina AG, Picassoplatz 8 4052 Basel Jens.Lachmann@iconplc.com phone: +41 79 593 4489
(BASEC)
Contact
Contact Person Switzerland
Jens Lachmann
+41 79 593 4489
Jens.Lachmann@cluttericonplc.comICON Clinical Research (Switzerland) GmbH c/o Experfina AG, Picassoplatz 8 4052 Basel
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Bern
(BASEC)
Date of authorisation
26.08.2025
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
Offene Verlängerungsstudie der Phase II zur Beurteilung der langfristigen Sicherheit und Verträglichkeit von oral verabreichtem Zasocitinib (TAK-279) bei Patienten mit mässiger bis schwerer aktiver Colitis ulcerosa und mässigem bis schwerem aktivem Morbus Crohn (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available